FDA Opioid Policy: Senate Takes A Speak Softly Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
Senate Appropriations Committee says FDA should finalize draft abuse-deterrent opioids guidance, but unlike House, does not make funding contingent on completion.
You may also be interested in...
FDA’s Regulatory Rock And Hard Place: How To Handle Draft Guidances
Republicans on the Senate HELP Committee say they are concerned that FDA is using draft guidance documents to set substantive policy, which they argue puts companies in a difficult position.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.
US FDA's CDER Creates Quantitative Medicine Center Of Excellence; Job Includes AI Oversight
The group will coordinate quantitative medicine issues throughout the FDA's Center for Drug Evaluation and Research to help streamline drug development.